A potent, equipotent CXCR1 and CXCR2 antagonist with IC50 of 31 nM and 21 nM, respectively.

A potent CXCR7 (ACKR3) agonist..

A potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively.

A potent and highly selective D4 dopamine receptor antagonist with Ki of 3.5 nM, >200-fold selectivity over D2 and D3 receptors.

A novel potent, slow tight binding LPA1 receptor antagonist with IC50 of 86 nM, Kd of 0.34 nM.

A novel potent, selective CXCR2 inhibitor with IC50 of 7.6 nM.

A novel potent, selective CXCR2 inhibitor with IC50 of 0.4 nM.

A novel potent and selective agonist of GPR84 that induces calcium response with EC50 of 0.213 uM.

A novel 5-HT receptor antagonist for the treatment of Parkinson's disease..

A moderately potent, but highly selective α2-adrenoceptor antagonist, the only reported selective antagonist at the α2B-adrenoceptor not having potent α1-adrenoceptor antagonist activity.

>98%,Standard References

(R)-Cetirizine is the (R)-enantiomer of the histamine H1 receptor antagonist and second generation antihistamine cetirizine.

(R)-(-)-Phenylephrine hydrochloride is a phenylephrine (PE) and an α1-adrenoceptor agonist

(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM.

(+)PD 128907 is a potent D3 dopamine receptor agonist (Ki = 2.3 nM). Displays 18 - 200-fold selectivity over other dopamine receptor subtypes.